Table 2. Summary of meta-analysis results.
PFS: progression-free survival, OS: Overall survival, ORR: overall response rate.
| Analysis | Therapy | HR | 95% CI | Result |
| OS | pembrolizumab | 1.00 | 0.94-1.07 | No statistically significant differences were observed between zolbetuximab and other inhibitors |
| sintilimab | 0.99 | 0.89-1.09 | ||
| sugemalimab | 0.98 | 0.87-1.10 | ||
| tislelizumab | 0.97 | 0.87-1.09 | ||
| zolbetuximab | 0.98 | 0.91-1.07 | ||
| nivolumab | 1.00 | - | ||
| PFS | pembrolizumab | 1.00 | 0.93-1.06 | No statistically significant differences were observed between zolbetuximab and other inhibitors |
| sintilimab | 0.91 | 0.83-1.00 | ||
| sugemalimab | 0.92 | 0.84-1.02 | ||
| tislelizumab | 0.93 | 0.84-1.03 | ||
| zolbetuximab | 0.96 | 0.88-1.05 | ||
| nivolumab | 1.00 | - | ||
| ORR | All regimens presented similar effects on ORR |